Back to top

Bull of the Day

We upgrade our recommendation on Accuray Inc. (ARAY) to Outperform following our assessment of its healthy second-quarter fiscal 2011 results and increased visibility on the stock. Earnings per share of $0.07 comfortably beat the Zacks Consensus Estimate of a loss of $0.02.

The company swung to profit in the quarter as a decline in operating expenses offset lower revenues. Accuray continues to enjoy strong demand for its CyberKnife robotic radiosurgery as reflected by increasing number of patients treated with the system.

Moreover, the company is expected to benefit from the recent recovery in hospital capital spending. We are also upbeat about the compelling prospect in radiation oncology rendered by the company's impending acquisition of rival TomoTherapy.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
SYNAPTICS I… SYNA 78.11 +8.14%
CENTURY ALU… CENX 19.88 +5.74%
GREEN PLAIN… GPRE 39.41 +5.12%
PILGRIM'S P… PPC 28.82 +3.08%
THE PANTRY… PTRY 18.41 +2.79%